Anti-IL-20 antibodies and binding partners and methods of using in inflammation
OwnerWenfeng Xu, Wayne Kindsvogel +6inventors
InventorsWenfeng Xu, Wayne Kindsvogel, Yasmin Chandrasekher, Stacey Dillon, Joyce Lehner, Anthony Siadak, Pallavur Sivakumar, Margaret Moore
Life of this patent
Estimating the term…
Abstract
The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-20 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. The present invention includes anti-IL-20 and anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-20 using such antibodies and binding partners.
Claims39
A method of producing an antibody to a polypeptide comprising:
- inoculating an animal with a polypeptide selected from the group consisting of:
- a) a polypeptide consisting of amino acid residues 42 (Ile) to 102 (Asp) of SEQ ID NO:8;
- b) a polypeptide consisting of amino acid residues 42 (Ile) to 60 (Ile) of SEQ ID NO:8;
- c) a polypeptide consisting of amino acid residues 42 (Ile) to 69 (Glu) of SEQ ID NO:8;
- d) a polypeptide consisting of amino acid residues 42 (Ile) to 81 (Cys) of SEQ ID NO:8;
- e) a polypeptide consisting of amino acid residues 42 (Ile) to 96 (Lys) of SEQ ID NO:8;
- f) a polypeptide consisting of amino acid residues 42 (Ile) to 102 (Asp) of SEQ ID NO:8;
- g) a polypeptide consisting of amino acid residues 60 (Ile) to 69 (Glu) of SEQ ID NO:8;
- h) a polypeptide consisting of amino acid residues 60 (Ile) to 81 (Cys) of SEQ ID NO:8;
- i) a polypeptide consisting of amino acid residues 60 (Ile) to 96 (Lys) of SEQ ID NO:8;
- j) a polypeptide consisting of amino acid residues 60 (Ile) to 102 (Asp) of SEQ ID NO:8;
- k) a polypeptide consisting of amino acid residues 69 (Glu) to 81 (Cys) of SEQ ID NO:8;
- l) a polypeptide consisting of amino acid residues 69 (Glu) to 96 (Lys) of SEQ ID NO:8;
- m) a polypeptide consisting of amino acid residues 69 (Glu) to 102 (Asp) of SEQ ID NO:8;
- n) a polypeptide consisting of amino acid residues 81 (Cys) to 96 (Lys) of SEQ ID NO:8;
- o) a polypeptide consisting of amino acid residues 81 (Cys) to 102 (Asp) of SEQ ID NO:8;
- and
- p) a polypeptide consisting of amino acid residues 96 (Lys) to 102 (Asp) of SEQ ID NO:8,
- wherein the polypeptide elicits an immune response in the animal to produce the antibody;
- and isolating the antibody from the animal;
- and wherein the antibody specifically binds to an IL-20 polypeptide (SEQ ID NO:8).
An antibody or antibody fragment that binds to a polypeptide comprising a sequence of amino acid residues as shown in SEQ ID NO:8;
- and reduces the pro-inflammatory activity of IL-20 (SEQ ID NO:8).
The antibody or antibody fragment according to claim 11, wherein the antibody or antibody fragment reduces the pro-inflammatory activity of either IL-20 (SEQ ID NO:8) or IL-22 (SEQ ID NO:6).
A method of treating a mammal afflicted with an inflammatory disease in which IL-20 plays a role, comprising:
- administering an antagonist IL-20 to the mammal such that the inflammation is reduced, wherein the antagonist comprising and antibody, antibody fragment, or binding polypeptide that specifically binds a polypeptide or polypeptide fragment of IL-22RA (SEQ ID NO:3) or is a polypeptide or polypeptide fragment of IL-22RA (SEQ ID NO:3);
- and wherein the inflammatory activity of IL-20 (SEQ ID NO:8) is reduced.
An antibody comprising a monoclonal antibody that that binds to an antigenic epitope of human IL-20 (SEQ ID NO:8) selected from the group consisting of:
- a) a polypeptide consisting of amino acid residues 42 (Ile) to 102 (Asp) of SEQ ID NO:8;
- b) a polypeptide consisting of amino acid residues 42 (Ile) to 60 (Ile) of SEQ iID NO:8;
- c) a polypeptide consisting of amino acid residues 42 (Ile) to 69 (Glu) of SEQ ID NO:8;
- d) a polypeptide consisting of amino acid residues 42 (Ile) to 81 (Cys) of SEQ ID NO:8;
- e) a polypeptide consisting of amino acid residues 42 (Ile) to 96 (Lys) of SEQ IfD NO:8;
- f) a polypeptide consisting of amino acid residues 42 (Ile) to 102 (Asp) of SEQ ID NO:8;
- g) a polypeptide consisting of amino acid residues 60 (Ile) to 69 (Glu) of SEQ ID NO:8;
- h) a polypeptide consisting of amino acid residues 60 (Ile) to 81 (Cys) of SEQ ID NO:8;
- i) a polypeptide consisting of amino acid residues 60 (Ile) to 96 (Lys) of SEQ ID NO:8;
- j) a polypeptide consisting of amino acid residues 60 (Ile) to 102 (Asp) of SEQ ID NO:8;
- k) a polypeptide consisting of amino acid residues 69 (Glu) to 81 (Cys) of SEQ ID NO:8;
- l) a polypeptide consisting of amino acid residues 69 (Glu) to 96 (Lys) of SEQ ID NO:8;
- m) a polypeptide consisting of amino acid residues 69 (Glu) to 102 (Asp) of SEQ ID NO:8;
- n) a polypeptide consisting of amino acid residues 81 (Cys) to 96 (Lys) of SEQ ID NO:8;
- o) a polypeptide consisting of amino acid residues 81 (Cys) to 102 (Asp) of SEQ ID NO:8;
- and
- p) a polypeptide consisting of amino acid residues 96 (Lys) to 102 (Asp) of SEQ ID NO:8,
- wherein the antibody reduces or neutralizes the activity of human IL-20 (SEQ ID NO:8).
Dependencies are inferred from the claim text.